close
MENU
Investment
3 mins to read

‘No comment’ from Pacific Edge on future capital raise

Cancer diagnostics company’s long wait for Medicare coverage determination ‘unchartered territory’, CEO Peter Meintjes says.

Key points
  • Revenue: Down 27% to $12.2 million in the six months to September 30.
  • Net loss: $14.5m, improved from a $15.3m loss last year.
  • Main takeaway: The company is not commenting on whether it needs to raise more capital while it continues to wait for a decision on whether its Cxbladder product will be funded by the US Medicare scheme.

Pacific Edge is not commenting on whether it will need to raise capital soon, instead focusing on potential 2025 catalysts against the ongoing headwind of whether its Cxbladder product will be funded by the US Medicare scheme.

The listed cancer diagnostics company today reported a net loss after tax

Want to read more? It's easy.

Choose your best value subscription option

Student

Exclusive offer for uni students studying at a New Zealand university (valued at $499).
Individual
Group membership
NBR Marketplace

Yearly Premium Online Subscription

NZ$499.00 / yearly

Monthly Premium Online Subscription

NZ$44.95 / monthly

Smartphone Only Subscription

NZ$24.95 / monthly

Premium Group Membership 10 Users

NZ$350+GST / monthly

$35 per user - Pay by monthly credit card debit

Premium Group Membership 20 Users

NZ$600+GST / monthly

$30 per user - Pay by monthly credit card debit

Premium Group Membership 50 Users

NZ$1250+GST / monthly

$25 per user - Pay by monthly credit card debit

Premium Group Membership 100 Users

NZ$1875+GST / monthly

$18.75 per user - Pay by monthly credit card debit

Yearly Premium Online Subscription + NBR Marketplace

NZ$499.00 / yearly

Already have an account? Login
Hamish McNicol Tue, 26 Nov 2024
Contact the Writer: Hmcnicol@nbr.co.nz
News tip? Question? Typo? Let us know: editor@nbr.co.nz
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
Key points
  • Revenue: Down 27% to $12.2 million in the six months to September 30.
  • Net loss: $14.5m, improved from a $15.3m loss last year.
  • Main takeaway: The company is not commenting on whether it needs to raise more capital while it continues to wait for a decision on whether its Cxbladder product will be funded by the US Medicare scheme.
Company profile
Powered by: nzx logo
Change:
Price
Previous Close
Turnover
Movement
Volume
Avg Daily Volume
Daily High
Daily Low
52 Week High
52 Week Low
‘No comment’ from Pacific Edge on future capital raise
Investment,
106882
true